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Parkinson’s disease (PD) is characterized by dopamine depletion in the putamen, which
leads to motor dysfunction. As the disease progresses, a substantial degree of dopamine
depletion also occurs in caudate and nucleus accumbens. This may explain a number
of neuropsychiatric manifestations, including depression, apathy, and cognitive decline.
Dopamine replacement therapy partially restores motor function but long-term treatment
is often associated with motor complications (motor fluctuations and dyskinesias). Positron
emission tomography (PET) studies suggest that the dopamine release rate is substantially
higher in PD subjects with motor complications compared to stable responders. Notably,
this differential pattern of dopamine release is already present in the early stages of the
disease, before motor complications become clinically apparent. Converging evidence sug-
gests that striatal dopamine depletion in PD leads to reduced plasticity in the primary
motor cortex and, presumably, in non-motor cortical areas as well. Although dopamine
replacement therapy tends to restore physiological plasticity, treatment-induced motor, and
neuropsychiatric complications could be related to abnormalities in corticostriatal synaptic
plasticity.
Keywords: dopamine, Parkinson’s disease, PET, motor function, fluctuations, dyskinesias, plasticity,
neuropsychiatric manifestations
INTRODUCTION
Parkinson’s disease (PD) has traditionally been defined accord-
ing to its motor manifestations. Bradykinesia, rigidity, and resting
tremor are the core clinical features and reflect the degree of
dopamine depletion in the putamen (1, 2). Recent years have
seen an increasing interest in neuropsychiatric manifestations of
the disease, some of which are likely related to dopamine deple-
tion in the caudate nucleus and nucleus accumbens (NAcc). In
fact, a putamen-caudate-accumbens gradient of dopamine deple-
tion, with dysfunction of the corresponding frontostriatal loops,
followed by dopamine depletion in the frontal cortex, has been
proposed to explain the sequential occurrence of motor symp-
toms and a great variety of neuropsychiatric manifestations (3). In
addition to the clinical picture observed during the “off” medica-
tion state, there are also treatment-related motor and non-motor
alterations. Dopaminergic (DA) therapies are able to normalize
motor function and may also help to correct neuropsychiatric
symptoms during the early stages of the disease. In the long-term,
however, these therapies are often associated with motor and non-
motor complications. Dyskinesias and impulse control disorders
(ICDs) are only two examples. There is compelling evidence to
suggest that dyskinesias are due to treatment-related abnormal-
ities occurring in the frontostriatal motor loop (4, 5). Likewise,
treatment-related abnormalities in the frontostriatal cognitive and
limbic loops could be responsible for ICDs. This short review arti-
cle will cover some of the most relevant contributions of dopamine
radiotracer neuroimaging to the understanding of motor and
neuropsychiatric manifestations of PD.
PET ASSESSMENTS OF DOPAMINERGIC FUNCTION
A number of positron emission tomography (PET) radio-
tracers can be used to assess the DA system. Presynaptically
(6), (1) [18F]-fluorodopa uptake provides an estimate of the
activity of the enzyme dopa-decarboxylase, (2) plasma mem-
brane dopamine transporter (DAT) radioligands (e.g., [11C]-
methylphenidate) provide an estimate of DAT site density, and
(3) vesicular monoamine transporter type 2 (VMAT2) radioli-
gands (e.g., [11C]-dihydrotetrabenazine) provide an estimate of
VMAT2 site density. Postsynaptically, [11C]-raclopride (a D2/D3
receptor antagonist) is the radioligand most frequently used to
estimate the density of dopamine D2/D3 receptors in the striatum,
where receptor concentrations are high. For extrastriatal areas
(e.g., frontal cortex), where D2/D3 receptor concentrations are
low, raclopride does not provide an optimal signal-to-noise ratio.
Here, high-affinity D2/D3 antagonists such as [18F]-fallypride and
[11C]-FLB-457 are better biomarkers (7, 8). A major advantage of
raclopride is its susceptibility to displacement by dopamine (5,
9). This allows comparisons between baseline and postactivation
scans in order to estimate the amount of dopamine released after
the activation of the DA system (e.g., after levodopa challenge).
In contrast, the ability of high-affinity radiotracers to quantify
dopamine release in extrastriatal areas seems to be limited.
DEGENERATION OF DOPAMINE PATHWAYS IN PD
Post-mortem biochemical studies have shown that PD has a
characteristic gradient of dopamine depletion in the striatum
(1, 2). The putamen is the most affected region, followed by
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dorsal caudate (d-Caud), ventral caudate (v-Caud), and NAcc.
Longitudinal PET studies have confirmed in vivo such a progres-
sive putamen-caudate gradient of DA dysfunction (10), although
specific subregions of the ventral striatum were not evaluated.
In all likelihood, this gradient of dopamine depletion reflects
the sequential degeneration of the nigrostriatal and mesolim-
bic dopamine pathways. Presumably, the mesocortical dopamine
pathway would be affected last, which would lead to cortical
dopamine depletion.
Based on the striatal gradient of dopamine depletion, three
major anatomical and functional frontostriatal loops are pre-
dicted to be sequentially affected in PD (3): first, the motor
loop, which connects cortical motor areas (including the sup-
plementary motor cortex and the primary motor cortex) with
the putamen; second, the cognitive loop, which connects the
dorsolateral prefrontal cortex (DLPFC) with the dorsal caudate
nucleus (d-Caud); and third, a “complex” limbic loop, with con-
nections (i) between the orbitofrontal cortex (OFC) and the v-
Caud nucleus (v-Caud), and (ii) between the anterior cingulate
cortex (ACC) and the NAcc (11–14). Over time, these frontostriatal
loop dysfunctions caused by dopamine depletion in the striatum
would be further complicated by cortical dopamine depletion
secondary to degeneration of the mesocortical dopamine path-
way – the direct DA projection to the frontal cortex. The degree
of frontal DA dysfunction might follow a gradient similar to
that proposed for the striatum (i.e., DLPFC>OFC>ACC) (15).
Dopamine neurons of the mesocortical pathway have unconven-
tional characteristics, including lack of DAT and D2 autorecep-
tors (16), which may limit their capability to undergo regulatory
adaptations.
DOPAMINE AND MOTOR MANIFESTATIONS OF PD
A distinction should be made between DA dysfunction “off” and
“on” medication.
STRIATAL DOPAMINERGIC DYSFUNCTION DURING THE “OFF”
MEDICATION STATE
A recent multi-tracer longitudinal PET study has demonstrated
in vivo that DA dysfunction in PD is particularly severe in the puta-
men (17). Using a VMAT2 marker ([11C]dihydrotetrabenazine –
DTBZ), it was estimated that some 70% of DA terminals must
be lost before the first motor symptoms occur (Figure 1), which
agrees with post-mortem estimates of striatal dopamine deple-
tion (80%) (1, 2). Different radiotracers offer, however, somewhat
different pictures (6). Thus, DAT radioligands tend to give more
severe estimates of DA dysfunction, probably reflecting compen-
satory downregulation of DAT sites in an attempt at maintaining
normal synaptic dopamine levels. In contrast, fluorodopa uptake
is relatively upregulated in PD, which may also represent a com-
pensatory mechanism. In consequence, there is a consensus that
VMAT2 radioligands probably provide more accurate estimates
of DA dysfunction (6), although VMAT2 binding may be also
subject to some degree of regulation (18). In general, bradyki-
nesia and rigidity scores (but not tremor scores) correlate with
the nigrostriatal DA deficit (19, 20). Imaging markers of DA dys-
function may not distinguish between idiopathic and monogenic
parkinsonism (21).
FIGURE 1 | Progression of putaminal dopaminergic (DA) dysfunction in
Parkinson’s disease (PD). DA dysfunction was estimated using normalized
[11C]dihydrotetrabenazine (DTBZ) binding data. The green straight segment
represents normal aging. The red curve corresponds to PD. Motor
symptoms begin at time 0 (in this case, at age 53 years, which was the
mean age of PD onset of the sample). A very similar PD curve was
obtained for the caudate nucleus (10). These observations suggest that the
nigrostriatal and mesolimbic dopamine pathways probably have the same
pattern of neurodegeneration. It remains unknown whether the same
applies to the mesocortical dopamine pathway. Adapted from Ref. (17).
Putaminal DTBZ binding curves obtained from longitudinal
PET data have provided important information on the progression
of PD. It has been estimated that the onset of DA pathology (loss of
DA terminals in the striatum) begins some 17 years before the first
motor symptoms appear (Figure 1). Notably, this presymptomatic
phase of the disease is longer in younger patients (25 years) com-
pared to older patients (10 years). Once motor symptoms begin,
there seems to be little progression after about 5–10 years into the
symptomatic phase of the disease. In fact, about 15% of putaminal
DA terminals still remain intact in very advanced PD stages (i.e.,
>30 years after motor symptom onset). These observations sug-
gest that a substantial part of the progression in motor dysfunction
that we see in our patients in the clinic may not reflect the progres-
sive loss of DA terminals, but maladaptive changes occurring in
dopamine-dependent frontostriatal loops. For example, a num-
ber of studies support the view that cortico-cerebello-thalamo-
cortical loops increase activity to compensate for dysfunctional
changes occurring in the cortico-striato-thalamo-cortical loops,
in an attempt to maintain near-normal motor function (22). In
the long-run, however, these initially beneficial compensations
may end up contributing to the development of motor compli-
cations (23). In addition, PD-related pathological changes (i.e.,
alpha-synuclein deposition) occurring in non-DA systems can also
contribute to the clinical progression.
STRIATAL DOPAMINERGIC DYSFUNCTION DURING THE “ON”
MEDICATION STATE
Dynamic PET studies with raclopride have revealed a number
of adaptations that occur in surviving DA terminals during the
symptomatic phase of PD. Among all the mechanisms involved in
the dopamine release-reuptake cycle, alterations of a parameter,
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namely the dopamine release rate, has been identified as the
most important risk factor for the development of treatment-
related motor complications (4). Specifically, patients with early
PD who will go on to develop motor complications (fluctuations
and dyskinesias) have a higher dopamine release rate than those
who will remain stable responders (9). This between-group differ-
ence increases over time, being particularly prominent once motor
complications become clinically relevant (5). At that time, fluc-
tuators and dyskinetics release very large amounts of dopamine
during the first hour after oral administration of levodopa. The
abnormal increase in levodopa-related dopamine release will lead
to (i) dyskinesias (reflecting large swings in synaptic dopamine lev-
els), (ii) fluctuations (whenever the dopamine reuptake system is
not efficient enough to maintain adequate presynaptic dopamine
levels for the following release-reuptake cycles), or (iii) a com-
bination of the two. In contrast, stable responders show a more
physiologic and sustained dopamine release process, maintain-
ing adequate synaptic dopamine levels during hours following
levodopa challenge. It should be emphasized that although PD
patients with motor complications have an increase in the release
of dopamine during the first hour after levodopa administration, it
does not mean that the overall synaptic levels of dopamine reach
above normal levels in PD. Levodopa treatment does normalize
vesicular dopamine levels in surviving striatal DA terminals but
the overall synaptic levels of dopamine remain below normal due
to the profound loss of striatal DA terminals (4, 5). In keeping with
this notion, dyskinetics often have residual parkinsonism during
the “on” medication state.
Interestingly, neurophysiologic studies using transcranial mag-
netic stimulation methods show that the differential pattern of
putaminal dopamine release (and the corresponding differential
pattern of putaminal dopamine receptor stimulation) observed
in patients with motor complications and stable responders has
a correlate in the frontostriatal motor loop (24). Thus, while lev-
odopa treatment is able to restore normal plasticity in the primary
motor cortex of stable responders, primary motor cortex plastic-
ity dramatically declines in patients with motor complications.
As there is some indication that differential patterns of dopamine
release may also occur in other striatal structures (caudate and
accumbens), the possibility exists that plasticity changes occur-
ring in the corresponding frontostriatal loops (i.e., cognitive and
limbic loops) could play a role in the pathogenesis of a number of
neuropsychiatric manifestations of PD. For example, ICDs could
be related to a relative overactivity of the mesolimbic dopamine
pathway (12, 25), in the same manner as dyskinesias are related to
a relative overactivity of the nigrostriatal dopamine pathway.
DOPAMINE AND NEUROPSYCHIATRIC MANIFESTATIONS
OF PD
MODEL OF NEUROPSYCHIATRIC MANIFESTATIONS
A recently reported PD-related frontostriatal cognitive dysfunc-
tion (PDFCD) staging model suggests that a number of neu-
ropsychiatric manifestations of the disease may follow a staging
of DA dysfunction in frontostriatal loops (3) (Figure 2). Accord-
ingly, fatigue, depression (OFF), and apathy would occur sequen-
tially in the “off” medication state. Likewise, ICDs, depression
(ON), and psychosis would be the corresponding neuropsychiatric
manifestations during the “on” medication state. ICDs, in partic-
ular, are proposed to be due to a relatively excessive DA drive
in non-motor frontostriatal loops, and could therefore be the
neuropsychiatric equivalent to dyskinesias.
The PDFCD stating is fundamentally based on the DA tone
present in different striatal structures (d-Caud, v-Caud, and
NAcc), and is supported by the sequential abnormalities observed
in tests that are specific for different frontostriatal loops (12,
25–28). The contribution of the direct mesocortical DA projec-
tion to loop-specific cortical areas (i.e., DLPFC, OFC, and ACC)
remains unclear, although fluorodopa PET studies suggest that
the DA tone in the frontal cortex may be upregulated in early
PD (29). Whether such, presumably compensatory, frontal DA
upregulation is region-specific for dysfunctional frontostriatal
loops remains unknown. Over time, however, frontal DA over-
activity is expected to disappear as the mesocortical dopamine
pathway becomes affected by PD pathology. Eventually, these
dopamine-related striatal and cortical functional alterations of the
frontostriatal loops would become complicated by the addition
of cortical PD pathology (i.e., alpha-synuclein deposition in the
frontal cortex).
Impulse control disorders
Impulse control disorders in PD are a group of neuropsychi-
atric manifestations associated with younger age, treatment with
dopamine agonists, and use of high doses of levodopa (30, 31).
The estimated prevalence is approximately 15%. Pathological
gambling, compulsive shopping, compulsive eating, and hyper-
sexuality are the most frequently reported ICDs. Compulsive DA
medication use, particularly levodopa abuse, is a related disorder
typically associated with younger age and depression. Punding
(excessive, unproductive repetitive motor actions) is also a com-
pulsive behavior sometimes encountered in PD. For simplicity, all
these abnormal behaviors can be considered under the umbrella
of ICDs, although the hedonic component may vary considerably
among them (e.g., it would be large in hypersexuality and relatively
low in punding).
The PDFCD model suggests that dysfunction of specific fron-
tostriatal loops plays a pivotal role in ICDs (Figure 2). Excessive
striatal DA activation of the loops connecting the v-Caud nucleus
with the OFC (v-Caud-OFC loop) and the NAcc with the ACC
(NAcc-ACC loop) has been implicated in the pathogenesis of
pathological gambling (32) and compulsive DA medication use
(33). These observations are in keeping with the reported increase
in amphetamine-induced release of dopamine in the striatum of
non-PD impulsive individuals, as estimated by [18F]-fallypride
binding changes (34). Interestingly, while raclopride PET studies
show that pathological gambling is associated with an increase in
the release of dopamine in the ventral striatum (32), dopamine
D2/D3 receptor availability (as estimated by [11C]-FLB-457 PET)
is increased in the ACC (35), suggesting that the mesocortical
dopamine pathway may indeed be underactive. ICDs could there-
fore be associated with increased DA tone in the ventral striatum
and decreased DA tone in the ACC. As mentioned earlier, evi-
dence from fluorodopa PET studies suggest that the mesocortical
dopamine pathway is overactive in early PD (29),perhaps as a com-
pensatory mechanism for striatal dopamine depletion. Hence, the
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FIGURE 2 | Parkinson’s disease related frontostriatal cognitive
dysfunction (PDFCD) staging with region-specific dopaminergic (DA)
tone. Predicted stage-specific DA function, both “off” and “on” medication
(OFF and ON), is shown for dorsal caudate (d-Caud), ventral caudate (v-Caud),
nucleus accumbens (NAcc), and frontal cortex. Although no distinction is
made between the frontal regions corresponding to the different frontostriatal
cognitive loops (i.e., dorsolateral prefrontal cortex, orbitofrontal cortex, and
anterior cingulate cortex), a gradient of DA dysfunction may be also present in
the mesocortical dopamine pathway (15). The DA tone can be optimal (0), too
low (negative values) or too high (positive values). The direct DA projection to
the frontal cortex seems to be initially upregulated (29), but with limited
capability to increase further the DA tone in response to DA treatment
because it lacks dopamine transporter sites and dopamine D2 autoreceptors
(16). ICDs= impulse control disorders. Adapted from Ref. (3).
DA underactivity observed in the ACC of PD patients with patho-
logical gambling could be also compensatory for the excess of DA
tone in the ventral striatum.
Depression and apathy
In contrast to PD patients with pathological gambling, who have
altered striatal and cortical DA homeostasis, with increased DA
tone in the ventral striatum and low DA tone in the ACC (35),
PD patients with apathy have reduced DA tone in both striatum
(ventral and dorsal striatum) and prefrontal cortex (36). Thus, as
predicted by the PDFCD model, apathy is associated with low DA
tone in the dorsolateral prefrontal, orbitofrontal, and ACC loops
(Figure 2). The model also predicts that depression and anxiety are
clinical predictors of apathy and may also reflect DA dysfunction.
In fact, mood and anxiety fluctuations sometimes mirror DA tone
changes in PD patients with motor fluctuations (37, 38), although
“on” medication depression can also occur. There is some evidence
that dopamine function may be also altered in non-PD individuals
with depression (39, 40). This may be particularly true of melan-
cholic depression, which is typically characterized by anhedonia
(41). Naturally, other DA and non-DA factors may also contribute
to depression and anxiety in PD. The amygdala, for example, which
is known to play an important role in anxiety disorders (42), can
undergo DA denervation as well as direct PD-related pathological
changes (43, 44).
Psychosis
The development of psychosis represents a later PDFCD stage,
where DA dysfunction affects not only the striatum (dorsal and
ventral striatum) but also the direct DA projection to the frontal
cortex (i.e., the mesocortical dopamine pathway) (Figure 2). Clini-
cally, psychosis is often preceded by relatively benign visual halluci-
nations, signaling the involvement of the NAcc – ACC loop. By the
time psychosis occurs, the “off” medication DA tone is predicted
to be low at both the striatal and cortical levels. It is tempting to
establish some conceptual parallelism between PD-psychosis and
schizophrenia. Converging evidence suggests that schizophrenia
is characterized by a hyperdopaminergic tone in the ventral stria-
tum associated with a hypodopaminergic tone in the frontal cortex
(45). The PDFCD model, on the other hand, suggests that a wide-
spread hypodopaminergic tone in both striatal and cortical areas,
even during the “on” medication state, may characterize psychosis
in PD. Nevertheless, hallucinations and psychosis in PD could be
due to large fluctuations in the level of DA stimulation occur-
ring during the “on” medication state rather than an overall hypo-
or hyperdopaminergic tone. This raises the possibility that some
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frontostriatal loops may be relatively overactive during the “on”
medication state, which would explain why, as with dyskinesias,
decreasing the dose of DA drugs is often helpful for ameliorat-
ing hallucinations and psychosis. Taking into account that the DA
tone in the frontal cortex is mostly determined by dopamine D1
receptors (46–48) and that hallucinations and psychosis are espe-
cially associated with the use direct dopamine D2 agonists (49, 50),
it seems reasonable to conclude that PD-psychosis is likely asso-
ciated with a relative hyperdopaminergic D2 tone in the NAcc.
Interestingly, [11C]-FLB-457 binding in the ACC decreases as PD
progresses (15), which could suggest a compensatory increase in
the activity of the direct DA projection to that frontal area. In
addition to striatal and cortical DA dysfunction, cortical alpha-
synuclein pathology can be a major determinant for the onset of
psychosis.
CONCLUDING REMARKS
Dopamine radiotracer neuroimaging has greatly contributed to
increase our understanding of motor and neuropsychiatric man-
ifestations of PD. It is becoming increasingly clear that many
of the clinical manifestations observed during the “on” state are
not the result of an average hyperdopaminergic tone, but are
due to the presence of large swings in synaptic dopamine lev-
els. This mechanism explains dyskinesias and may also apply
to ICDs and psychosis. Further research is needed to better
characterize the progression of DA dysfunction and plasticity
changes in different frontal regions and the corresponding clinical
correlates.
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